Approved indications
Ultomiris is approved to treat: (1) paroxysmal nocturnal hemoglobinuria (PNH) in adults and children ≥1 month; (2) atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy in adults and children ≥1 month; (3) anti‑AChR antibody–positive generalized myasthenia gravis (gMG) in adults; and (4) anti‑AQP4 antibody–positive neuromyelitis optica spectrum disorder (NMOSD) in adults.

Off-label uses
Clinicians may consider Ultomiris off label for other rare complement-mediated conditions on a case-by-case basis, but evidence outside the approved indications is limited to small studies or case reports, so its benefits and risks in those settings are less certain.

Efficacy expectations in PNH and aHUS
In PNH, many patients show rapid reductions in markers of hemolysis (such as LDH), fewer breakthrough hemolysis episodes, and less need for transfusions, with benefits often seen within days to weeks and maintained long term when infusions are continued. In aHUS, platelet counts and markers of clotting and hemolysis typically improve within the first weeks, and many patients experience better kidney function or stabilization, especially when treatment is started early.

Efficacy in gMG
In adult gMG trials, patients receiving Ultomiris had clinically meaningful improvements in daily function and muscle weakness scores by about 4–8 weeks, with continued gains or maintenance through at least 6 months; some patients respond earlier, while others may need longer to notice substantial changes.

Efficacy in NMOSD
In NMOSD, Ultomiris markedly reduced the risk of relapse attacks compared with placebo in clinical studies, helping many patients remain relapse free during follow-up, which is important to prevent new vision loss or paralysis.

Comparison with similar drugs
Compared with eculizumab (Soliris), an earlier C5 inhibitor, Ultomiris provides similar protection against complement-mediated damage but uses a longer-acting design, so most adults need maintenance infusions only every 8 weeks instead of every 2 weeks, while maintaining high rates of disease control and low relapse or breakthrough rates when dosed correctly.

General dosing pattern
Ultomiris is given only as an intravenous infusion in a clinic or infusion center. Dosing is weight based and always starts with a one-time loading dose, followed 2 weeks later by maintenance infusions. Most adults (for PNH, aHUS, gMG, and NMOSD) receive maintenance infusions every 8 weeks, while smaller pediatric patients may receive infusions every 4 or 8 weeks depending on weight.

How infusions are given
Each infusion is prepared by healthcare professionals, diluted into an IV bag, and infused over about 30–60 minutes for most adults, followed by at least 1 hour of observation for infusion-related reactions. You can eat and drink normally unless your clinic instructs otherwise, but you should arrive well hydrated and bring your medications list and Ultomiris Patient Safety Card to every visit.

Special dosing instructions
You must receive required meningococcal vaccinations (and sometimes short-term antibiotics) before or just after starting Ultomiris, as directed by your prescriber. If you need plasma exchange, plasmapheresis, or intravenous immunoglobulin (IVIG), tell your treating team, because these procedures can lower Ultomiris levels and may require an additional dose on a specific schedule. Do not change your infusion dates on your own; any adjustment should be coordinated by your specialist.

Missed dose guidance
If you miss or expect to miss an infusion appointment, contact your healthcare provider immediately; they will reschedule you as soon as possible and adjust the schedule if needed. Do not wait until your next regular date and do not try to “double up” infusions.

Overdose
Overdose is unlikely because infusions are prepared by professionals, but if you ever believe you have received too much medication or develop unusually severe or unexpected side effects after an infusion, seek urgent medical care and inform the treating team of the exact drug and dose you received.

Common side effects
The most common side effects vary somewhat by condition but often include: upper respiratory tract infections (such as colds or sinus infections), headache, diarrhea, nausea or vomiting, back or joint pain, fever, and high blood pressure in some aHUS patients. These are usually mild to moderate and tend to occur early in treatment, but any persistent or bothersome symptom should be reported to your healthcare team.

Serious or rare adverse effects
Because it blocks complement, Ultomiris greatly increases the risk of serious, life-threatening meningococcal infections (sepsis or meningitis) and can also increase susceptibility to other serious bacterial infections. Warning signs include sudden fever, headache with stiff neck, rash, extreme tiredness, confusion, vomiting, light sensitivity, shortness of breath, or body aches; these require emergency medical attention. Serious infusion-related reactions (including allergic reactions with chest pain, trouble breathing, swelling of the face, tongue, or throat, or feeling faint), severe infections (including pneumonia or COVID-19), and, rarely, sepsis have been reported.

Warnings and precautions
Before starting Ultomiris, you must receive recommended meningococcal vaccines (and sometimes antibiotics) and be enrolled in the required REMS safety program in the United States. Use with caution if you have any active infection or fever. It is not known if Ultomiris is safe in pregnancy; it is generally reserved for situations where the potential benefit outweighs risks, and careful monitoring is needed. Because it is unknown if the drug passes into breast milk and it persists in the body, breastfeeding is usually avoided during therapy and for several months after the last dose. No specific dose adjustments are defined for kidney or liver disease, but these conditions may increase infection risks and require closer monitoring.

Overall safety profile
Within the complement inhibitor class, Ultomiris has a safety profile generally similar to eculizumab, with the major concern being serious meningococcal and other infections, balanced by fewer infusion visits due to its longer dosing interval. Most patients can remain on long-term therapy with stable safety when carefully vaccinated, monitored, and treated promptly for infections.

Side-effect monitoring and reporting
Tell your healthcare provider promptly about any new or worsening symptoms, especially signs of infection or infusion reactions. Side effects can be reported directly to the FDA through the MedWatch program (online or at 1-800-FDA-1088) or to the manufacturer’s safety line, which is listed in the Medication Guide and on the Patient Safety Card.

Drug and treatment interactions
Ultomiris has few traditional drug–drug interactions, but certain therapies can affect how it works. Plasma exchange, plasmapheresis, and intravenous immunoglobulin (IVIG) can remove the drug from your bloodstream and usually require supplemental dosing on a schedule determined by your specialist. Newer neonatal Fc receptor (FcRn) blockers (such as efgartigimod) may lower Ultomiris levels if used together, so this combination is usually avoided or monitored very closely. Other complement inhibitors (such as eculizumab) are generally not given at the same time except during carefully supervised transitions.

Other medicines, vaccines, food, and alcohol
Many people on Ultomiris also take immunosuppressants, steroids, blood pressure medicines, anticoagulants, or antiepileptics; these can increase overall infection or bleeding risk and require regular follow-up but are not direct chemical interactions with Ultomiris. You should receive all recommended non-live vaccines, and your team may delay or avoid certain live vaccines while you are on therapy. There are no known specific interactions with foods or moderate alcohol intake, but excess alcohol can worsen liver function, immunity, or other medicines you may take, so ask your clinician what is safe for you.

Conditions and co-medications needing caution
Use Ultomiris very cautiously if you have any active systemic infection, history of recurrent serious infections, or cannot receive meningococcal vaccines, as the risk of life-threatening infection may be unacceptably high. People with severe heart or lung disease, advanced kidney failure, or those on multiple strong immunosuppressants may need closer monitoring and faster treatment of even minor infections.

Monitoring needs
Your team may monitor blood counts, markers of hemolysis and clotting, kidney function, and blood pressure, along with neurologic or visual exams for gMG and NMOSD. At every visit you should be screened for infection symptoms and reminded about the urgent warning signs of meningococcal disease. Always carry and show your Patient Safety Card so any provider who treats you in an emergency knows that you are receiving a complement inhibitor.

Q: How often will I need Ultomiris infusions?
A: After a one-time loading dose, most adults receive one intravenous infusion every 8 weeks; smaller children may need infusions every 4 or 8 weeks depending on body weight, and your specialist will set a schedule tailored to you.

Q: How soon might I feel better after starting Ultomiris?
A: Some people with PNH or aHUS notice improvement in symptoms and lab results within days to weeks, while in generalized myasthenia gravis and NMOSD, meaningful changes often appear over several weeks and continue to build with regular infusions.

Q: Why do I need meningococcal vaccines before taking Ultomiris?
A: Because Ultomiris blocks part of your immune system, it greatly increases your risk of dangerous meningococcal infections, so vaccines (and sometimes short-term antibiotics) are required to reduce, though not eliminate, this risk.

Q: Can I stop Ultomiris once I feel better?
A: Stopping or stretching infusions without a plan from your specialist can lead to return or worsening of disease, and in PNH or aHUS may increase the risk of serious clotting events, so any change should be carefully planned and monitored.

Q: Is Ultomiris safe during pregnancy or breastfeeding?
A: It is not known exactly how Ultomiris affects an unborn baby or passes into breast milk, so its use in pregnancy or breastfeeding is reserved for situations where benefits clearly outweigh risks and requires close coordination between your specialist and obstetric or pediatric providers.

Q: Will Ultomiris interact with my other medications?
A: Ultomiris has few direct drug interactions, but treatments like plasma exchange, IVIG, FcRn blockers, or other complement inhibitors can affect its levels or duplicate effects, so always tell every healthcare provider and pharmacist that you are on Ultomiris and carry an up-to-date medication list.

Storage
Patients typically do not store Ultomiris at home; the unopened vials are kept by the pharmacy or infusion center refrigerated at 2°C–8°C (36°F–46°F) in the original carton, protected from light, and must not be frozen or shaken.

At-home considerations
If you are ever given medication or diluted solution to bring to an infusion visit, keep it in the original packaging, follow the written refrigeration instructions exactly, and transport it in an insulated cooler as directed by your care team.

Disposal
Any unused drug, used vials, IV bags, needles, and tubing should be discarded as medical waste by healthcare professionals; do not throw these items into household trash or recycling and do not flush them down the toilet.

Patient materials
Keep your Ultomiris Patient Safety Card in a safe, easy-to-reach place (such as your wallet) and bring it to all medical and dental appointments.